FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib), a first in class RAS inhibitor for adults with metastatic pancreatic adenocarcinoma following prior systemic ther…
Impact analysis · 65/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The FDA approved Rasonque (daraxonrasib), a first in class RAS inhibitor for adults with metastatic pancreatic adenocarcinoma following prior systemic therapy or ineligible for multiagent treatment. The approval is final.
Quantitative evidence
- 500 patients enrolled in randomized phase 3 RASolute 302 trial
- Median overall survival 13.2 vs 6.7 months (hazard ratio 0.40; p<0.0001)
- Median progression‑free survival 7.2 vs 3.6 months (hazard ratio 0.49; p<0.0001)
- Pricing or commercial availability timeline
- Long‑term safety profile
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Daraxonrasib is an oral multi‑selective RAS(ON) inhibitor that nearly doubled survival versus chemotherapy in a pivotal phase 3 trial.
Market context
The approval gives Revolution Medicines, Inc. a first‑in‑class commercial oncology product in a high‑unmet‑need market; pricing data not yet disclosed.
Legal and regulatory context
This constitutes final FDA approval; the agency used priority review, breakthrough and orphan designations, plus the National Priority Voucher pilot program.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 99356a2e840a2d0b98a3c2eb4821812cb55e73736d732b7f2820ce24d2150470
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-08-26T213011Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.